LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Bath, Philip M.W.; Martin, Renée H.; Palesch, Yuko; Cotton, Daniel; Yusuf, Salim; Sacco, Ralph L.; Diener, Hans-Christoph; Toni, Danilo; Estol, Conrado; Roberts, Robin (2009)
Publisher: American Heart Association Inc
Languages: English
Types: Article
Subjects:
Background and Purpose—High blood pressure (BP) is common in acute ischemic stroke and associated independently\ud with a poor functional outcome. However, the management of BP acutely remains unclear because no large trials have\ud been completed.\ud \ud Methods—The factorial PRoFESS secondary stroke prevention trial assessed BP-lowering and antiplatelet strategies in\ud 20 332 patients; 1360 were enrolled within 72 hours of ischemic stroke, with telmisartan (angiotensin receptor\ud antagonist, 80 mg/d, n647) vs placebo (n713). For this nonprespecified subgroup analysis, the primary outcome was\ud functional outcome at 30 days; secondary outcomes included death, recurrence, and hemodynamic measures at up to 90\ud days. Analyses were adjusted for baseline prognostic variables and antiplatelet assignment.\ud \ud Results—Patients were representative of the whole trial (age 67 years, male 65%, baseline BP 147/84 mm Hg, small artery disease 60%, NIHSS 3) and baseline variables were similar between treatment groups. The mean time from stroke to recruitment was 58 hours. Combined death or dependency (modified Rankin scale: OR, 1.03; 95% CI, 0.84–1.26; P0.81;\ud death: OR, 1.05; 95% CI, 0.27–4.04; and stroke recurrence: OR, 1.40; 95% CI, 0.68–2.89; P0.36) did not differ between the treatment groups. In comparison with placebo, telmisartan lowered BP (141/82 vs 135/78 mmHg, difference 6 to 7 mmHg and 2 to 4 mmHg; P0.001), pulse pressure (3 to 4 mmHg; P0.002), and rate-pressure product (466 mmHg.bpm; P0.0004).\ud \ud Conclusion—Treatment with telmisartan in 1360 patients with acute mild ischemic stroke and mildly elevated BP appeared\ud to be safe with no excess in adverse events, was not associated with a significant effect on functional dependency, death, or recurrence, and modestly lowered BP.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ounpuu S, Lawson WA, Palesch Y, Martin RH, Albers GW, Bath PM, Bornstein N, Chan BPL, Chen S-T, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick PB, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig G, P P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voight T, Weber M, Yoon B-W. for the PROFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225-1237.
    • 2. Sacco RL, Diener H-C, Yusuf S, Cotton D, Ounpuu S, Lawton W, Palesch Y, Martin R, Albers GW, Bath PM, Bornstein N, Chan BPL, Chen S-T, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick PB, Gu V, Hermansson K, Hillbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voight T, Weber M, Yoon B-W. the PROFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359: 1238 -1251.
    • 3. The ENOS Trial Investigators. Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int J Stroke. 2006;1:245-249.
    • 4. Geeganage C, Bath PMW. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database of Systematic Reviews. 2008;Issue 4.
    • 5. Blood pressure in Acute Stroke Collaboration (BASC). Vasoactive drugs for acute stroke Cochrane Database of Systematic Reviews. 2000;Issue 4.
    • 6. Britton M, Carlsson A, de Faire U. Blood pressure course in patients with acute stroke and matched controls. Stroke. 1986;17:861- 864.
    • 7. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG. for the IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke. 2002;33:1315-1320.
    • 8. Carlsson A, Britton M. Blood pressure after stroke. A one-year follow-up study. Stroke. 1993;24:195-199.
    • 9. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension. 2004;43: 18 -24.
    • 10. Sprigg N, Gray LJ, Bath PMW, Boysen G, De Deyn PP, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Ringlestein B, van der Sande J-J, Lindenstrom E. for the TAIST investigators. Relationship between outcome and baseline blood pressure and other haemodynamic mreasures in acute ischaemic stroke: data from the TAIST trial. J Hypertens. 2006;24: 1413-1417.
    • 11. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane Database of Systematic Reviews. 2000;Issue 1.
    • 12. Wahlgren NG, MacMahon DG, de Keyser J, Indredavik B, Ryman T. INWEST Study Group. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovascular Diseases. 1994;4:204 -210.
    • 13. Ahmed N, Nasman P, Wahlgren NG. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke. 2000;31:1250 -1255.
    • 14. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke (“BEST” trial): an evaluation. BMJ. 1988;296: 737-741.
    • 15. Schrader J, Luders S, Kulchewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener H-C, Dominiak P. The ACCESS Study. Evaluation of acute candesartan therapy in stroke survivors. Stroke. 2003;34:1699 -1703.
    • 16. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet. 2009;8:48 -56.
    • 17. Sare GM, Gray LJ, Bath PMW. Effect of antihypertensive agents on cerebral blood flow and flow velocity in acute ischaemic stroke: systematic review of controlled studies. J Hypertens. 2008;26:1058 -1064.
    • 18. Willmot M, Ghadami A, Whysall B, Clarke W, Wardlaw J, Bath PM. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke. Hypertension. 2006;47:1209 -1215.
    • 19. Diener H-C, Sacco RL, Yusuf S. for the Steering Committee and PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and Telmisartan versus placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes trial (PRoFESS). Cerebrovascular Diseases. 2007;23:368 -380.
    • 20. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit. 1996;1:55- 61.
    • 21. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Can we improve the statistical analysis of stroke trials? Statistical re-analysis of functional outcomes in stroke trials. Stroke. 2007;38:1911-1915.
    • 22. Bath PMW, Geeganage CM, Gray LJ, Collier T, Pocock S. Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published stroke trials. Stroke. 2008;39:2817-2823.
    • 23. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J. 1995;108:710 -717.
    • 24. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
    • 25. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Sung Kim J, Ling Tao Q, Dong Jiang J, Wen Tia L, Xu E, Cheng Y, Heritier S, Morgenstern LW, Chalmers J; for the INTERACT Investigators. Intensive blood pressure reduction in actue cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008;7:391-399.
    • 26. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457-507.
  • No similar publications.

Share - Bookmark

Cite this article